Global AI Impact Summit 2026, India: Owkin strengthens its strategic partnerships with India to advance biological artificial super intelligence

• Owkin partners with Omics Bank and 4baseCare to turn fragmented data into AI-ready intelligence
• Owkin offers K Pro to drive faster, more inclusive drug discovery and AI-enabled care

Bangalore, Paris - 18th February 2026 - Owkin, the only agentic AI company founded and led by an oncologist, has established partnerships with Indian healthcare and genomics leaders Omics Bank, and 4baseCare. 

OmicsBank provides access to large-scale multimodal clinical and multi-omics datasets from historically underrepresented regions, strengthening the foundation for more globally representative research. 4baseCare, a global precision oncology company powered by genomics, AI, and real-world clinico-genomic data, building a new standard of cancer care that isi inclusive, data-driven, and reflective of the genomic diversity of the world we live in.

Both organisations are committed to addressing the persistent underrepresentation of Asian and Middle Eastern populations in drug R&D, a gap that can limit treatment relevance given important genetic and environmental differences. Together, we aim to develop solutions built on more representative datasets, enabling more inclusive research, more robust therapeutic development, and more equitable standards of cancer care worldwide.

Owkin, creator of the first “Agent for Biology,” K Pro - designed to connect research to care - is now seeking to expand collaborations with top Indian hospitals, data providers and pharmaceutical companies.

Owkin is seeking partnerships with Indian institutions to accelerate pharmaceutical and healthcare growth, using K Pro to leverage the country’s expertise and vast healthcare data for faster, more inclusive drug development while moving towards AI-enabled care.

Owkin’s AI models can unlock the value embedded in fragmented biomedical data by mapping and transforming it into structured, AI-ready assets. Once unlocked, these data are available (through Owkin’s K Pro agent) to drive smarter biopharma pipeline decisions to continuously enhance pharmaceutical research in India. Regular integration of insights from relevant patient data enables better more inclusive biological insights, stronger hypothesis validation and more rapid translation into clinical application.

Thomas Clozel, CEO and Co-founder, Owkin said:

“We are on a mission to build biological artificial superintelligence to cure all disease. Global patient data is the key to unlocking this. We are excited to enhance our collaborations in India to turn fragmented datasets into meaningful discoveries for more inclusive therapeutic breakthroughs.” 

Sumit Sinha, CEO, OmicsBank said:

‍“At OmicsBank, our focus has always been on building AI-ready data infrastructure that unlocks the full value of real-world and multi-omics data from emerging markets in a responsible and scalable way. Partnering with Owkin allows us to extend this capability globally and help ensure that diverse patient populations are more accurately represented across the drug development lifecycle”  

Kshitij Rishi, COO & Co-founder, 4baseCare said:

‍“Precision oncology is only as strong as the data behind it. At 4baseCare, we build inclusive genomic datasets reflecting the diversity of Asian and Middle Eastern patients and combine them with advanced AI to enable more informed treatment decisions. We are proud to partner with Owkin to ensure underrepresented populations are meaningfully included in global research and next-generation drug development.”

‍

Press Contact: malika.labou-ext@owkin.com

‍

‍